Do you defer bispecific antibody therapy in CAR-T-eligible patients with relapsed myeloma to keep CAR-T viable as a future option?

At this point in time, if I think that a patient is a good candidate for CAR-T therapy, I recommend that they pursue CAR-T prior to receiving a bispecific. Exceptions to this would be if there is a clinical trial available or if talquetamab is used as bridging therapy, but I would not administer a b...

Currently, this is probably one of the most difficult clinical management questions in myeloma – and the old statement of asking 2 different myeloma specialists and receiving 5 different opinions is very appropriate.

Over the years following the introduction of a new myeloma therapy, we have learnt ...

A Carvykti CAR-T has the highest response proportion and may have the longest PFS in patients with relapsed myeloma who have received one prior line of therapy, and my general approach is to always use my best treatment first, as you never know whether this will be the patient's last line of therapy...